<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755765</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0736</org_study_id>
    <secondary_id>1R61AT009622-01A1</secondary_id>
    <nct_id>NCT03755765</nct_id>
  </id_info>
  <brief_title>Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics</brief_title>
  <acronym>YOBIOTIC</acronym>
  <official_title>Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of the study is to better understand the mechanisms causing antibiotic-associated&#xD;
      diarrhea (AAD) and how probiotics may prevent some of the iatrogenic effects of antibiotic&#xD;
      medications. One of the most common indications for probiotics is for prevention of&#xD;
      antibiotic-associated diarrhea. Clinically, different probiotic strains have demonstrated the&#xD;
      ability to prevent AAD; however, the mechanism of action behind this effect has not been&#xD;
      elucidated. Data from several studies suggest that antibiotic-induced disruption of commensal&#xD;
      bacteria in the colon results in a significant (up to 50%) reduction in short chain fatty&#xD;
      acid (SCFA) production and a concomitant reduction in Na-dependent fluid absorption resulting&#xD;
      in AAD. Probiotics have been shown to ameliorate a variety of gastrointestinal disease states&#xD;
      and thus, the study investigators hypothesize that administration of a probiotic yogurt will&#xD;
      protect against the development of AAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics are live microorganisms that, when administered in adequate amounts, confer a&#xD;
      health benefit on the host. One of the most common indications for probiotic treatment is the&#xD;
      prevention of antibiotic-associated diarrhea (AAD). Unfortunately, the efficacy of many&#xD;
      probiotic products used for AAD is not supported by rigorous independent research, and&#xD;
      non-evidence-based clinical usage is common. Data from several studies are consistent with&#xD;
      the notion that antibiotic-induced disruption of commensal bacteria in the colon results in a&#xD;
      significant reduction of short chain fatty acid (SCFA) production and a concomitant reduction&#xD;
      in Na-dependent fluid absorption resulting in AAD. The probiotic strain being studied,&#xD;
      Bifidobacterium animalis subsp. lactis BB-12 (BB-12), has been shown to ameliorate a variety&#xD;
      of gastrointestinal disease states and is known to produce acetate at concentrations up to 50&#xD;
      mM in vitro. Thus, the investigators hypothesize that administration of BB-12 at the same&#xD;
      time as antibiotic consumption will protect against the development of AAD through its&#xD;
      ability to generate acetate directly, and also increase other SCFAs through cross-feeding of&#xD;
      certain bacteria in the Firmicutes phylum such Clostridium, Eubacterium and Roseburia, which&#xD;
      use acetate to produce butyrate.&#xD;
&#xD;
      The primary aim of the R61 phase (N=60) is to determine the ability of BB-12 to impact&#xD;
      antibiotic-induced reduction in SCFA as reflected by the levels of acetate, the most abundant&#xD;
      primary colonic SCFA. The primary hypothesis is that antibiotics will result in a reduction&#xD;
      in fecal SCFA, but BB-12 supplementation will protect against antibiotic-induced SCFA&#xD;
      reduction and/or be associated with a more rapid return to baseline SCFA levels as compared&#xD;
      to controls. Antibiotics also result in a decrease in total microbial counts and diversity in&#xD;
      the gut microbiota, disrupting the homeostasis of the gut ecosystem and allowing colonization&#xD;
      by pathogens. The secondary aim will be to determine the ability of BB-12 to impact&#xD;
      antibiotic-induced disruption of the gut microbiota with 16S ribosomal ribonucleic acid&#xD;
      (rRNA) profiling. The secondary hypothesis is that antibiotics will result in a decrease in&#xD;
      the overall number and diversity of bacterial species present in the fecal microbiota, and&#xD;
      further BB-12 supplementation will protect against antibiotic-induced shifts in the&#xD;
      microbiota and/or will be associated with a more rapid return to a baseline microbiota&#xD;
      composition as compared to controls. The long-term goal is to determine the impact of BB-12&#xD;
      on a variety of gastrointestinal disease states and ages, through high-level independent&#xD;
      research. This mechanism elucidation is important for directing future translational and&#xD;
      effectiveness research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Actual">January 8, 2020</completion_date>
  <primary_completion_date type="Actual">January 8, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline levels of fecal short-chain fatty acid at day 7</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in baseline number of bacterial species in fecal microbiota</measure>
    <time_frame>day 7, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline diversity of bacterial species in fecal microbiota</measure>
    <time_frame>day 7, 14</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline levels of fecal short-chain fatty acid</measure>
    <time_frame>day 14, 21, 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in baseline number of bacterial species in fecal microbiota</measure>
    <time_frame>day 21, 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in baseline diversity of bacterial species in fecal microbiota</measure>
    <time_frame>day 21, 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in baseline diarrhea/stool frequency</measure>
    <time_frame>day 7, 14, 21, 30</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Antibiotic-associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet</intervention_name>
    <description>Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet</description>
    <arm_group_label>BB-12</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BB-12</intervention_name>
    <description>Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt</description>
    <arm_group_label>BB-12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has the ability to read, speak, and write in English&#xD;
&#xD;
          2. Has refrigerator (for proper storage of the study yogurt)&#xD;
&#xD;
          3. Has reliable telephone access&#xD;
&#xD;
          4. Is between ages of 18-65 years&#xD;
&#xD;
          5. Agree to refrain from eating yogurts, yogurt drinks, and other foods specified in the&#xD;
             provided What Not to Eat list&#xD;
&#xD;
          6. Agree to collect stool samples and participate in follow-up calls as specified&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes or asthma that requires medication&#xD;
&#xD;
          2. Allergy to strawberry&#xD;
&#xD;
          3. Active diarrhea (three or more loose stools per day for two consecutive days)&#xD;
&#xD;
          4. Any gastrointestinal (or digestive tract) medications, i.e. medicines for irritable&#xD;
             bowel syndrome, gastroesophageal (acid) reflux disease, inflammatory bowel disease,&#xD;
             etc.&#xD;
&#xD;
          5. History of heart disease, including valvulopathies or cardiac surgery, any implantable&#xD;
             device or prosthetic&#xD;
&#xD;
          6. History of gastrointestinal surgery or disease&#xD;
&#xD;
          7. Lactose intolerance that prevents participant from eating yogurt&#xD;
&#xD;
          8. Allergy to milk-protein&#xD;
&#xD;
          9. Allergy to any component of the product or the yogurt vehicle&#xD;
&#xD;
         10. Allergy to penicillin or cephalosporin class antibiotics&#xD;
&#xD;
         11. Allergy to any of the following medications: a) Penicillin; b) Erythromycin; c)&#xD;
             Tetracycline; d) Trimethoprim; e) Ciprofloxacin&#xD;
&#xD;
         12. Women who are breastfeeding, pregnant, or planning to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Merenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Fraser, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Department of Family Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Daniel Merenstein</investigator_full_name>
    <investigator_title>Director of Research Programs</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03755765/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

